Tresiba and Apixaban Interaction: What Patients and Clinicians Should Know

Why These Two Drugs Are Frequently Co-Prescribed

Patients with type 2 diabetes face a significantly higher burden of atrial fibrillation (AF) and venous thromboembolism (VTE), making co-prescription of insulin and an anticoagulant common in clinical practice. The overlap is not coincidental. Diabetes and thrombotic disease share metabolic and vascular pathology.

The Framingham Heart Study identified diabetes as an independent risk factor for AF, with a hazard ratio of 1.4 for men and 1.6 for women after adjustment for other cardiovascular risk factors [1]. Among patients with established AF, the CHA₂DS₂-VASc score already awards one point for diabetes, reflecting the elevated stroke risk in this population [2]. Once anticoagulation is indicated, apixaban has become a first-line choice. In the ARISTOTLE trial (N=18,201), apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year; HR 0.79 to 95% CI 0.66, 0.95) with a 31% reduction in major bleeding [3]. The subgroup analysis of ARISTOTLE patients with diabetes (25% of the trial population) showed consistent benefit, with no signal of differential efficacy or safety [4].

Insulin degludec, marketed as Tresiba, is prescribed when basal insulin is required for glycemic control in type 1 or type 2 diabetes. Its ultra-long duration of action (half-life exceeding 25 hours) and flat pharmacokinetic profile distinguish it from older basal insulins [5]. The result: large numbers of patients take both drugs daily.

Pharmacokinetic Interaction Analysis: No Conflict at the Enzyme Level

Insulin degludec and apixaban are processed by entirely separate metabolic pathways, which is why no pharmacokinetic interaction exists between them. The distinction matters clinically.

Apixaban is metabolized primarily by CYP3A4, with minor contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2J2. It is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) [6]. Strong dual inhibitors of CYP3A4 and P-gp (ketoconazole, ritonavir, clarithromycin) increase apixaban exposure by approximately 100%, prompting the FDA to recommend dose reduction to 2.5 mg twice daily when co-administered with these agents [6]. Strong CYP3A4 and P-gp inducers (rifampin, phenytoin, carbamazepine) decrease apixaban exposure by roughly 50% and should be avoided [6].

Insulin degludec, by contrast, is a 49-amino-acid peptide hormone. It does not interact with cytochrome P450 enzymes. It does not bind P-gp. Its elimination occurs through general proteolytic degradation, identical to the catabolism of endogenous insulin [5]. The Tresiba prescribing information from the FDA states: "No formal drug interaction studies have been performed with Tresiba. The pharmacokinetic and pharmacodynamic properties of insulin degludec are not expected to be altered by drugs that affect CYP pathways" [5].

This means insulin degludec cannot inhibit, induce, or compete for the enzymes and transporters that govern apixaban clearance. The reverse is equally true. Apixaban does not affect insulin receptor binding, glucose transporter activity, or peptide hormone degradation.

What Major DDI Databases Report

All three leading drug interaction databases, Lexicomp, Micromedex, and Clinical Pharmacology, classify the insulin degludec/apixaban combination as having no known pharmacokinetic interaction. This is consistent across all insulin formulations and all four approved DOACs (apixaban, rivaroxaban, edabanxa, dabigatran).

The American Diabetes Association Standards of Care (2025) do not list anticoagulants among drugs requiring insulin dose adjustment [7]. Similarly, the 2024 ESC Guidelines for Management of Atrial Fibrillation do not flag insulin therapy as a modifier of DOAC dosing [8].

Dr. Craig January, lead author of the 2019 AHA/ACC/HRS AF Guideline update, noted: "The direct oral anticoagulants have a much narrower drug interaction profile than warfarin. Insulin products, including long-acting analogs, do not interact with any of the four approved DOACs" [9].

Indirect Clinical Risks That Still Require Attention

The absence of a direct drug-drug interaction does not mean the combination is free of clinical considerations. Two indirect risks deserve monitoring.

Hypoglycemia and fall-related bleeding. Severe hypoglycemia causes neuroglycopenic symptoms (confusion, loss of consciousness, seizures) that increase fall risk. In anticoagulated patients, a fall can produce serious bleeding complications, including intracranial hemorrhage. The DEVOTE trial (N=7,637) demonstrated that insulin degludec reduced the rate of severe hypoglycemia by 40% compared with insulin glargine U100 (HR 0.60 to 95% CI 0.48, 0.76; P<0.001) [10]. This hypoglycemia advantage is one reason clinicians may prefer degludec over glargine in patients who are simultaneously anticoagulated.

Dr. John Buse, director of the University of North Carolina Diabetes Center, stated in the DEVOTE analysis: "The significantly lower rate of severe hypoglycemia with degludec is clinically meaningful, particularly in older patients on polypharmacy regimens where falls carry outsized consequences" [10].

Diabetic nephropathy and apixaban clearance. Approximately 27% of apixaban elimination depends on renal excretion [6]. Progressive diabetic kidney disease reduces glomerular filtration rate, which can raise apixaban plasma concentrations over time. The Eliquis prescribing information specifies a dose reduction from 5 mg to 2.5 mg twice daily in patients who meet at least two of the following three criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL [6]. In patients with end-stage renal disease on dialysis, limited pharmacokinetic data are available. The 2021 KDIGO guidelines recommend against routine use of DOACs when eGFR falls below 15 mL/min/1.73 m² [11].

For patients on insulin degludec who have declining renal function, clinicians should recheck serum creatinine and eGFR at least every 6 months to determine whether apixaban dose modification is warranted.

Monitoring Protocol for Co-Prescribed Patients

Routine therapeutic drug monitoring of apixaban levels is not recommended for most patients, including those on insulin degludec. Instead, a structured clinical monitoring approach addresses the indirect risks outlined above.

Glycemic monitoring. Continuous glucose monitoring (CGM) or structured self-monitoring of blood glucose (SMBG) should be used to identify hypoglycemic episodes. Target a time-below-range (<70 mg/dL) of less than 4% per the international consensus on CGM metrics [12]. Any increase in hypoglycemia frequency warrants insulin dose reduction and reassessment of fall risk.

Renal function. Measure serum creatinine and calculate eGFR at baseline, then every 6 to 12 months. In patients with eGFR <60 mL/min/1.73 m², increase frequency to every 3 to 6 months. Apply the apixaban dose-reduction criteria at each check.

Bleeding assessment. Ask about bruising, gum bleeding, hematuria, melena, and hemoptysis at every visit. The HAS-BLED score can stratify bleeding risk, and diabetes itself does not add a point, but concomitant renal dysfunction, uncontrolled hypertension, and older age do [13].

Hepatic function. Both drugs have hepatic considerations. Apixaban is contraindicated in severe hepatic impairment (Child-Pugh C) [6]. Insulin requirements may fluctuate with hepatic disease due to altered gluconeogenesis and reduced insulin clearance. Check liver function tests annually or when clinical suspicion arises.

Switching From Warfarin to Apixaban in Insulin-Treated Patients

Patients with diabetes who were previously managed on warfarin may be transitioned to apixaban. This switch eliminates the need for INR monitoring and removes the dozens of CYP2C9/VKORC1-mediated food and drug interactions that complicate warfarin management.

The transition protocol is straightforward: discontinue warfarin, and once the INR falls below 2.0, initiate apixaban at the appropriate dose (5 mg or 2.5 mg BID based on dose-reduction criteria) [6]. No insulin dose adjustment is needed during or after the switch.

A post-hoc analysis of the ARISTOTLE trial found that patients with diabetes who received apixaban had a 36% lower rate of major bleeding compared with warfarin-treated diabetic patients (HR 0.64 to 95% CI 0.46, 0.89), a reduction even more pronounced than in the overall trial population [4]. This finding supports preferential use of apixaban over warfarin in the insulin-treated diabetic population, where polypharmacy complexity and adherence burden are already high.

Other Tresiba Drug Interactions Worth Knowing

While apixaban poses no pharmacokinetic concern, several drug classes do require attention when co-prescribed with insulin degludec.

Drugs that increase hypoglycemia risk. Sulfonylureas, meglitinides, GLP-1 receptor agonists, and SGLT2 inhibitors can all potentiate insulin-induced hypoglycemia when added to degludec. The Tresiba label specifically lists ACE inhibitors, MAO inhibitors, salicylates, and sulfonamide antibiotics as agents that may increase the blood-glucose-lowering effect of insulin [5].

Drugs that decrease insulin efficacy. Corticosteroids, thiazide diuretics, atypical antipsychotics (olanzapine, clozapine), and protease inhibitors can raise blood glucose and may necessitate degludec dose increases [5].

Thiazolidinediones. Pioglitazone and rosiglitazone, when combined with insulin, increase the risk of fluid retention and heart failure. The FDA label carries a boxed-section warning for this combination [5].

None of these interactions involve CYP-mediated mechanisms. They are pharmacodynamic. Apixaban does not share any of these pharmacodynamic pathways.

Patient Counseling Points

Patients taking both Tresiba and Eliquis should receive clear guidance on three topics.

First, both medications can be taken at the same time of day without separation. There is no absorption interaction. Tresiba is injected subcutaneously, while apixaban is taken orally. The routes of administration do not overlap.

Second, if a patient experiences a severe hypoglycemic episode (confusion, loss of consciousness, inability to self-treat), someone nearby should call emergency services. The bleeding risk from a fall while anticoagulated makes prompt treatment of severe hypoglycemia more urgent than in non-anticoagulated patients.

Third, patients should not stop either medication without consulting their prescriber. Discontinuing apixaban abruptly increases stroke risk in AF patients [6]. Discontinuing insulin degludec causes hyperglycemia and potential diabetic ketoacidosis in type 1 diabetes [5]. Inform patients of 90-day prescription refill timelines so they do not experience gaps in either therapy.